Woojin B&G Obtains Patent Related to Recombinant Capripoxvirus 2c Antigen Protein
[Asia Economy Reporter Minwoo Lee] Woojin BNJ announced on the 27th that it has obtained a patent titled 'Recombinant Canine Parvovirus 2c Antigen Protein and Its Uses' in collaboration with the Director of the Animal and Plant Quarantine Agency of the Ministry of Agriculture, Food and Rural Affairs and BioApp.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- Electronic Financial Services Revenue Surpasses 12 Trillion Won Last Year... Number of Non-Compliant Companies Rises to 29
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
The company stated, "Using the recombinant expression vector and the transformed recombinant plant, this patent enables rapid and highly efficient production of the canine parvovirus 2c antigen protein, which is being developed as a vaccine for companion animals," adding, "We plan to promote commercialization both domestically and internationally through this."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
